Article
Biochemistry & Molecular Biology
Ming-Fang Wu, Yen-Hsiang Huang, Ling-Yen Chiu, Shur-Hueih Cherng, Gwo-Tarng Sheu, Tsung-Ying Yang
Summary: Curcumin induces apoptosis in chemoresistant lung cancer cells through generation of ROS, and p38 MAPK is identified as a crucial signaling pathway for this process.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Izabela Zarczynska, Monika Gorska-Arcisz, Alexander Jorge Cortez, Katarzyna Aleksandra Kujawa, Agata Malgorzata Wilk, Andrzej Cezary Skladanowski, Aleksandra Stanczak, Monika Skupinska, Maciej Wieczorek, Katarzyna Marta Lisowska, Rafal Sadej, Kamila Kitowska
Summary: The study explores the acquired resistance mechanism to a novel selective FGFR inhibitor in NSCLC cell lines, finding that upregulated p38 expression/phosphorylation and enhanced MAPK signaling gene expression are associated with resistance. Inhibition of p38 restores sensitivity to the inhibitor, highlighting p38 MAPK as a driver of resistance to novel FGFR inhibitors and providing insights for targeted therapy in NSCLC.
Article
Integrative & Complementary Medicine
Weijuan Huang, Yanqing Wang, Tingsha He, Jianhua Zhu, Jianhuan Li, Sirui Zhang, Yong Zhu, Yafang Xu, Lv Xu, Haoran Wang, Rongmin Yu, Liyan Song
Summary: Art B, a natural compound, has potential effects on cisplatin resistance in non-small cell lung cancer (NSCLC). It enhances cisplatin effectiveness by increasing Cx43 expression and promoting drug uptake. Combination therapy with cisplatin and Art B shows better therapeutic effect than individual treatments. Art B affects intracellular Fe2+ levels, calcium influx, and gap junction and MAPK pathways, contributing to its effects.
AMERICAN JOURNAL OF CHINESE MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Chunyin Tang, Jieting Liu, Chunsong Yang, Jun Ma, Xuejiao Chen, Dongwen Liu, Yao Zhou, Wei Zhou, Yunzhu Lin, Xiaohuan Yuan
Summary: Researchers have made crucial advances in understanding the pathogenesis and therapeutics of non-small cell lung cancer (NSCLC). Despite improved survival rates, there is still a need for the development of novel drugs or combination therapies with less toxicity. Curcumin and its analogs show potential as therapeutic agents for NSCLC treatment, although clinical trial results have been inconsistent. This review collects and analyzes the latest reports on the anti-NSCLC mechanisms of curcumin and its analogs in combination with other chemotherapeutic agents.
Article
Biochemistry & Molecular Biology
Nazilah Abdul Satar, Mohd Nazri Ismail, Badrul Hisham Yahaya
Summary: This study demonstrates the potential of curcumin as a chemosensitizer for targeting cancer stem cell subpopulations in non-small cell lung cancer. Curcumin reduces cellular proliferation and inhibits self-renewal capability of lung cancer stem cells, while also regulating the stem cell niche to inhibit chemoresistance and cancer-related protein expression.
Article
Biology
Huiling Zhou, Li Zhou, Qing Guan, Xuyang Hou, Cong Wang, Lijun Liu, Jian Wang, Xinfang Yu, Wei Li, Haidan Liu
Summary: Skp2, an E3 ligase, is overexpressed in NSCLC and is associated with the downregulation of MLKL, a regulator of necroptosis. Inhibition of Skp2 enhances the efficacy of cisplatin, a chemotherapy drug, in NSCLC and inhibits tumor growth. Mechanistically, Skp2 promotes the ubiquitination-mediated degradation of MLKL in cisplatin-resistant NSCLC cells.
COMMUNICATIONS BIOLOGY
(2023)
Article
Oncology
Swati Misri, Kirti Kaul, Sanjay Mishra, Manish Charan, Ajeet Kumar Verma, Martin P. Barr, Dinesh K. Ahirwar, Ramesh K. Ganju
Summary: This study demonstrates that cannabidiol (CBD) inhibits the growth and metastasis of drug-resistant non-small cell lung cancer cells (NSCLC) and induces apoptosis of cisplatin-resistant cells. It acts through the TRPV2 receptor and modulates oxidative stress pathways. CBD could be a promising therapeutic strategy for cisplatin-resistant NSCLC.
Article
Medicine, Research & Experimental
Hong-Wei Xia, Zhi-Qiang Zhang, Jun Yuan, Qing-Ling Niu
Summary: High levels of RECQL5 were found in major subtypes of NSCLC, LUAD and LUSC, and were associated with poor prognosis in LUAD. RECQL5 promoted NSCLC metastasis and hindered response to cisplatin therapy, suggesting its potential as a biomarker or clinical target for NSCLC.
Article
Oncology
Xiaoxue Xie, Steven H. Lin, James W. Welsh, Xiong Wei, Hekun Jin, Radhe Mohan, Zhongxing Liao, Ting Xu
Summary: This study identified age, tumor size, lung V5 and mean dose, heart V5 and mean dose, and XRCC1 rs25487 AA genotype as factors associated with severe RIL in lung cancer patients. Age, lung V5, and XRCC1 rs25487 AA were independently associated with a higher risk of severe RIL.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Yubo Yan, Xiangyuan Jin, HaoBo Sun, Sainan Pang, Xianglong Kong, Jianlong Bu, Shidong Xu
Summary: The study revealed that miR-139-5p alleviates the metastasis of NSCLC cells and their resistance against cisplatin by regulating YAF2 and the AKT/p38 MAPK signaling pathway. There is a targeting relationship between miR-139-5p and YAF2, and both overexpression of miR-139-5p and knockdown of YAF2 can reverse the DDP resistance in NSCLC cells, suggesting a potential novel target for improving the therapeutic effect on NSCLC.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Genetics & Heredity
Shulei Gong, Shiyang Wang, Mingrui Shao
Summary: Methyltransferase-like 14 (METTL14) mediates N-6-methyladenosine (m(6)A) modification to facilitate non-small cell lung cancer (NSCLC) cell resistance to cisplatin (DDP) via the miR-19a-5p/RBM24/AXIN1 axis.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2022)
Article
Oncology
Jing Zhuang, Jianjun Fan, Lihuan Zhu, Lilan Zhao, Yangyun Huang, Xiaojie Pan, Tianxing Guo
Summary: This study found that miR-452-5p can regulate the cell proliferation, migration, and invasion ability of NSCLC through targeting MSN, and it also affects the EMT process. These findings might provide a novel prevention and treatment target for NSCLC.
Article
Medicine, General & Internal
Sravani Ramisetty, Prakash Kulkarni, Supriyo Bhattacharya, Arin Nam, Sharad S. Singhal, Linlin Guo, Tamara Mirzapoiazova, Bolot Mambetsariev, Sandeep Mittan, Jyoti Malhotra, Evan Pisick, Shanmuga Subbiah, Swapnil Rajurkar, Erminia Massarelli, Ravi Salgia, Atish Mohanty
Summary: Translational research in medicine involves collaboration between scientists from different disciplines to apply knowledge from basic sciences to clinical practice. This approach, known as 'Team Medicine', focuses on addressing specific medical goals through partnership between basic science researchers and clinicians. Using cisplatin resistance in non-small cell lung cancer (NSCLC) as an example, this study demonstrates how a 'Team Science' approach was used to identify a previously approved compound that can alleviate cisplatin resistance in NSCLC. It also highlights the potential of a 'Team Medicine' approach in understanding resistance mechanisms and developing strategies to overcome drug resistance in NSCLC.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Hedieh Sadat Shamsnia, Mahtab Roustaei, Danial Ahmadvand, Alexandra E. Butler, Dorsa Amirlou, Sanam Soltani, Saeideh Momtaz, Tannaz Jamialahmadi, Amir Hossein Abdolghaffari, Amirhossein Sahebkar
Summary: Curcumin, a herbal remedy, possesses anti-inflammatory, antioxidant, and anticancer properties and impacts various signaling pathways including NF-KB, ROS, Wnt, JAK/STAT. P38, a part of the MAPK signaling pathway, plays a crucial role in inflammation, cell differentiation, proliferation, motility, and survival. Extensive evidence confirms that curcumin exerts anti-inflammatory, neuroprotective, and apoptotic effects by modulating the P38 MAPK signaling pathway.
INFLAMMOPHARMACOLOGY
(2023)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)